Cormedix (STU:19KA) FFO


STU:19KA Cormedix Inc STU:19KA
44 GF Score
Price €7.46
GF Value €56.45
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Cormedix FFO?

FFO (Funds from operations) only applies to REITs.

STU:19KA
44GF Score
Cormedix Inc STU:19KA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cormedix (STU:19KA) Overvalued in 2026?

Based on GuruFocus' analysis, Cormedix stock appears to be undervalued. The current stock price of €7.46 is trading 86.8% below its estimated GF Value™ of €56.45. GuruFocus considers Cormedix to be Possible Value Trap.

Key valuation signals for STU:19KA:

  • FFO:
  • GF Value™: €56.45 vs. price of €7.46 (86.8% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the STU:19KA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cormedix Business Description

Other Exchanges CRMD:USA
Address 389 Interpace Parkway, Suite 450, Parsippany, NJ, USA, 07054
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
44GF Score

Get the complete analysis for STU:19KA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.46
Price
€56.45
GF Value